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Abstract
The relationship between insulin secretion and acute insulin resistance (as assessed by Homeostatic Model Assessment 
[HOMA] index) and clinical and biochemical parameters in the early phase of non-diabetic ST-elevation myocardial 
infarction (STEMI) is so far unexplored. We aimed at assessing this relation in 286 consecutive STEMI patients without 
previously known diabetes submitted to primary percutaneous coronary intervention (PCI). Insulin resistance (as 
indicated by HOMA) was detectable in 67.1%. Non-parametric correlation showed that HOMA index was significantly 
correlated with BMI (r = 0.242; p < 0.0001) and HbA1c (r = 0.189; p < 0.001). At multivariable backward linear regression 
analysis, glycaemia was directly related to leukocyte count (p = 0.0003), age (p = 0.0001), creatine kinase isoform MB 
(CK-MB) (p = 0.00278) and lactate (p < 0.0001). Insulin was directly and significantly related to glycaemia (p = 0.0006), 
body mass index (BMI) (p = 0.00028) and lactate (p = 0.0096) In the early phase of STEMI without previously known 
diabetes the acute glucose dysmetabolism is quite complex, comprising increased glucose values and the development 
of acute insulin resistance. While insulin secretion is strictly related to BMI, apart from glucose levels, increased glucose 
values can be mainly related to the acute inflammatory response (as indicated to leukocyte count and C-RP), to age and 
to the degree of myocardial damage (as inferred by CK-MB) 
Keywords
Acute insulin resistance, acute phase, HOMA index, hyperglycaemia, STEMI 
role of insulin resistance, evaluated by means of Homeostatic 
Model Assessment (HOMA) index, in the early phase of 
acute myocardial infarction.13,14 In non-diabetic STEMI 
patients submitted to percutaneous coronary intervention 
(PCI), we reported that insulin resistance, as assessed by 
HOMA-index, is quite common and helps in the early risk 
stratification, since it represents an independent predictor 
for in-hospital mortality.15 More recently, Garcia et al.16 
observed that hyperinsulism was the most important factor 
associated with the occurrence of new cardiovascular 
events at long-term follow-up in Colombian patients with 
acute myocardial infarction, thus emphasising the prognos-
tic role of insulin resistance even at long term. 
Introduction
In the setting of acute myocardial infarction (MI),1 hypergly-
caemia is not simply a marker of pre-existing diabetes or 
glucose intolerance but part of the stress response to myocar-
dial injury mainly related to acute catecholamine release.2,3 
In patients with ST elevation myocardial infarction 
(STEMI) hyperglycaemia is common and, though fre-
quently untreated, associated with an increased risk of 
death.4-7 In these patients, increased glucose values hold a 
prognostic role when measured not only on admission 4 but 
also throughout hospital stay.8-11 We recently12 observed 
that, in non-diabetic STEMI patients, the poorer in-hospital 
glucose control was associated with higher mortality; peak 
glycaemia >180 mg/dl was associated with the highest 
mortality, whereas patients with peak glycaemia between 
140 and 180 mg/dl exhibited intermediate mortality rates. 
In the acute phase of STEMI, increased glucose levels 
have been related to the extent of myocardial injury and to 
the stress inflammatory response, but data on this topic are 
scarce and controversial. 
Insulin resistance is known to be part of the glyco- 
metabolic response to stress, but few studies assessed the 
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The relationship between insulin secretion and acute 
insulin resistance (as assessed by HOMA index) and clini-
cal and biochemical parameters in the early phase of non-
diabetic STEMI is so far unexplored; we aimed to assess 
this relation in 286 consecutive STEMI patients without 
previously known diabetes submitted to primary PCI. 
Study population
From 1 January 2008 to 31 December 2009, 286 consecu-
tive patients with STEMI (within 12 hours of symptoms’ 
onset) and without previously known diabetes were admit-
ted to our Intensive Cardiac Care Unit (ICCU), which is 
located at a tertiary centre. In our hospital, in Florence, the 
reperfusion strategy of STEMI patients is represented by 
primary PCI.11,14,15-18 STEMI patients are first evaluated by 
the Medical Emergency System staff in the pre-hospital set-
ting and then directly admitted to the catheterisation labora-
tory or transferred to it after a rapid stabilisation in First 
Aid. After primary PCI, they are admitted to our ICCU.
A successful procedure was defined as an infarct artery 
stenosis <20% associated with TIMI (Thrombolysis In 
Myocardial Infarction) grade 3 flow. Failure PCI was 
defined as resulting in TIMI grade 0 to 2 flow, regardless of 
the residual stenosis.19
The diagnosis of STEMI was based on the criteria of 
the American College of Cardiology/American Heart 
Association.20
On ICCU admission, after PCI, in a fasting blood sample 
the following parameters were measured: glucose (mg/dl), 
troponin I (ng/ml), insulin (mU/L), uric acid (mg/dl), 
C-reactive protein (C-RP, mg/dl) (normal values <9), 
alanine aminotransferase (ALT), aspartate amino transferase 
(AST), gamma-glutamyl transferase (GGT) NT-pro brain 
natriuretic peptide (NT-BNP, pg/ml),16 total cholesterol (mg/
dl), triglycerides (mg/dl), HDL, thyroid stimulating hor-
mone (TSH, pg/ml) and fibrinogen (mg/dl). Creatinine (mg/
dl) was also measured in order to calculate glomerular filtra-
tion rate (ml/min/1.73 m2).21 Glucose, Tn I, ALT and AST 
were measured three times per day during ICCU-stay and 
peak values for each variable were considered. 
Transthoracic two-dimensional echocardiography was 
performed on ICCU admission in order to measure left ven-
tricular ejection fraction (LVEF).
Definition of insulin resistance
Criteria used for the definition of insulin resistance are in 
accordance with the recently published guidelines proposed 
by the European Group of the study of Insulin Resistance 
(EGIR).22 HOMA was calculated according to the follow-
ing formula: {[fasting insulin (µU/ml)] × [fasting glucose 
(mmol/L)]}/22.5. Subjects whose values exceeded the sex-
specific 75th percentile (i.e. 1.80 for females and 2.12 for 
males) were considered to have insulin resistance 
(HOMA-IR).15,23 The study protocol was in accordance 
with the Declaration of Helsinki and approved by the local 
Ethics Committee. Informed consent was obtained in all 
patients before enrolment. 
Statistical analysis 
Data have been entered in a dedicated database and proc-
essed by means of SPSS 13.0 statistical package (SPSS 
Inc., Chicago, IL, USA). A two-tailed p-value <0.05 was 
Table 1. Clinical characteristics of patients included in the study.
Median (25th– 75th 
percentile) or 
frequency (%)
Age (years) 65 (57–75)
Males/females 215/71 (75.2/24.8%)
History of:
 Smoking, n (%) 186 (65.0%)
 COPD 21 (7.3%)
 Previous PCI 33 (11.5%)
 Previous AMI 35 (12.2%)
 Hypertension 117 (40.9%)
Estimated GFR (ml/min per 1.73 m2) 84.9 (69.2–102.9)
AMI location
 Anterior 155 (54.2%)
 Inferior 114 (39.9%)
 Other 17 (5.9%)
Coronary artery disease
 1-vessel 121 (42.3%)
 2-vessel 89 (31.1%)
 3-vessel 76 (26.6%)
 LM 18 (6.3%)
 CABG 2 (0.7%)
PCI failure 14 (4.9%)
EF (%) 45 (35–50)
Latency (minutes) 210 (160–322)
Drugs on admission
 Clopidogrel 98.2 (281/286)
 Unfractioned heparin 88.8 (254/286)
 IIaIIIb glycoprotein inhibitors 74.8 (214/286)
 Nitrates 68.2 (195/286)
 Betablockers 62.2 (178/286)
 ACE-inhibitors/ARB 87.1 (249/286)
 Statins 94.1 (269/286)
 Inotropes 9.8% (28/286)
In-hospital mortality 11 (3.8%)
COPD: chronic obstructive pulmonary disease, PCI: percutaneous 
coronary intervention, MI: myocardial infarction, GFR: glomerular 
filtration rate, LM: left main coronary artery, EF: ejection fraction,  ACE: 
angiotensin concerting enzyme, ARB: angiotensin receptor blockade
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Table 2. Comparison between patients with and without HOMA positivity.
HOMA positivity
n=192 (67.1%)
HOMA negativity
n=94 (32.9%)
p-value
Mann–Whitney U-test or 
Fisher’s exact test or χ2
Males/females 146/46 (76.0/24.0%) 69/25 (73.4/26.6%) 0.663
Age (years) 66 (56–75) 64 (57–76) 0.714
BMI (kg/m2) 26.3 (24.5–28.0) 25.1 (23.1–27.0) <0.001
Estimated GFR (ml/min per 1.73m2) 81.8 (66.0–101.4) 87.7 (73.1–106.8) 0.060
AMI location
0.304
 Anterior 110 (57.3%) 45 (47.9%)
 Inferior 72 (37.5%) 42 (44.7%)
 Other 10 (5.2%) 7 (7.4%)
Killip class
0.849
 I 157 (81.8%) 78 (83.0%)
 II 17 (8.8%) 6 (6.4%)
 III 5 (2.6%) 2 (2.1%)
 IV 13 (6.8%) 8 (8.5%)
EF (%) 42 (35–50) 45 (37–52) 0.168
PCI failure 12 (6.3%) 2 (2.1%) 0.154
Mortality 6 (3.1%) 5 (5.3%) 0.350
Glucose (mg/dl) 138 (116–166) 111 (99–130) <0.001
Peak glucose (mg/dl) 154 (133–187) 130 (114–153) <0.001
HbA1c >6.5% 27 (14.1%) 6 (6.4%) 0.075
Tn I (ng/ml) 107.3 (53.0–209.5) 61.6 (21.9–157.2) 0.002
NT-proBNP (pg/ml) 1253 (400–3,206) 1241 (529–2,505) 0.732
Uric acid (mg/dl) 5.6 (4.7–6.8) 5.4 (4.2–6.2) 0.053
ESR (mm/h) 22 (13–37) 24 (12–42) 0.865
Leucocytes (counts/ml) 11875 (9,320–14,670) 10375 (8,602–12,545) 0.001
CRP positivity 99 (51.6%) 58 (61.7%) 0.129
Fibrinogen (mg/dl) 378 (325–466) 383 (329–448) 0.778
ALT (U/L)
 Admission 44 (28–82) 31 (18–50) <0.001
 Peak 64 (44–101) 41 (25–90) <0.001
 Discharge 37 (28–54) 30 (18–45) 0.003
AST (U/L)
 Admission 90 (47–200) 57 (29–115) <0.001
 Peak 248 (135–416) 128 (68–314) <0.001
 Discharge 60 (35–98) 46 (33–74) 0.059
GGT (U/L) 32 (22–63) 24 (17–46) 0.004
Cholesterol (mg/dl) 199 (166–229) 186 (159–204) 0.004
HDL(mg/dl) 41 (36–49) 40 (35–45) 0.120
LDL(mg/dl) 134 (102–156) 124 (100–140) 0.015
Triglycerides (mg/dl) 98 (77–146) 92 (70–124) 0.159
TSH (mU/l) 0.93 (0.43–1.55) 1.00 (0.56–1.80) 0.166
HOMA: Homeostatic Model Assessment, BMI: body mass index, GFR: glomerular filtration rate, AMI: acute myocardial infarction, EF: ejection fraction, 
PCI: percutaneous coronary intervention, NT-pro-BNP, N terminal pro-brain natriuretic peptide, ESR: erythrocyte sedimentation rate, CRP: C-reac-
tive protein, AST: alanine amino transferase, ASP: aspartate amino transferase, GGT: gamma glutamyl transferase, TSH: thyroid stimulating hormone 
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considered statistically significant. Data of insulin resist-
ance subgroups are reported as frequencies (percentages) 
and medians (25th–75th percentile) and were analysed by 
Fisher’s exact test (categorical variables) and Mann–
Whitney U-test (continuous variables, which resulted in 
almost all non-normally distributed). Correlations between 
insulin resistance, as assessed by HOMA index, and clini-
cal, procedural and biochemical data have been investi-
gated in a univariable way by means of Spearman’s rho. 
A linear regression analysis investigated the correlation 
insulin versus glycaemia. By means of two multivariable 
backward linear regression analyses we explored the 
adjusted correlations of glycaemia and, respectively, 
insulinaemia, with clinical and biochemical variables and 
the respective final models have been reported. The initial 
model was constructed choosing as candidate variables 
those that significantly differed between subgroups or 
were known to be clinically relevant. A backward stepwise 
linear regression analysis was performed, after assessing 
for linearity, in order to find predictors for in-ICCU mor-
tality. The stepwise procedure (performed using a proba-
bility of the likelihood ratio test <0.05 for inclusion and 
<0.10 for exclusion) ran until all of the remaining candi-
date variables resulted significantly related to the outcome. 
Hagelkerke R2 and Hosmer–Lemeshow goodness-of-fit 
test are also reported. 
Results
Table 1 shows the clinical characteristics of patients included 
in the study. Males were prevalent (75.2%). Anterior myo-
cardial infarction was the most frequent location (54.2%). 
The incidence of PCI failure was 4.9% while in-ICCU mor-
tality rate was 3.8%. 
As depicted in Table 2, insulin resistance (as indicated by 
HOMA positivity) was detectable in 67.1%. Patients with 
insulin resistance showed a higher BMI (p < 0.001) and 
higher values of admission glucose, peak glucose, Tn I, leu-
kocytes and GGT (<0.001, <0.001, p = 0.002, p = 0.001 and 
p = 0.004 respectively). No difference was detectable 
between subgroups in HbA
1c
. Liver transaminases (ALT and 
AST) were significantly higher in insulin-resistant patients 
on admission, during ICCU stay and at discharge. In-ICCU 
mortality rate was comparable while the incidence of PCI 
failure showed a trend which did not reach statistical signifi-
cance. Patients with HOMA positivity exhibited higher val-
ues of total cholesterol (p = 0.004) and LDL (p = 0.015). 
Table 3 shows the comparison between patients with insulin 
resistance and those without, after exclusion of patients with 
HbA
1c
 >6.5% (33 patients, 11.5%); only parameters which 
were significantly different were reported. Patients with 
insulin resistance exhibited a higher BMI (p < 0.001) and 
higher values of admission glucose, peak glucose, Tn I, 
Table 3. Comparison between patients with and without  HOMA positivity after exclusion of patients with glycated Hb >6.5%. 
HOMA positivity  
n=165 (65.2%)
HOMA negativity 
n=88 (34.8%)
p-value
Mann–Whitney U-test 
or Fisher’s exact test
BMI (kg/m2) 26.3 (24.5–27.7) 25.1 (22.9–27.0) <0.001
Glucose (mg/dl) 131 (114–158) 111 (99–126) <0.001
Peak glucose (mg/dl) 148 (131–179) 128 (113–150) <0.001
Tn I (ng/ml) 107.0 (52.6–218.0) 60.9 (21.6–155.6) 0.002
Leucocytes (counts/ml) 11,730 (9,320–14,700) 10,420 (8,640–12,650) 0.005
CRP positivity 82 (49.7%) 55 (62.5%) 0.064
ALT (U/L)
 Admission 43 (29–84) 31 (18–50) <0.001
 Peak 65 (44–102) 41 (25–90) <0.001
 Discharge 38 (28–55) 30 (18–45) 0.002
AST (U/L)
 Admission 85 (41–199) 59 (29–116) 0.002
 Peak 255 (134–415) 128 (68–314) <0.001
 Discharge 59 (35–102) 44 (33–74) 0.063
GGT (U/L) 31 (22–64) 23 (16–42) 0.002
Cholesterol (mg/dl) 203 (169–233) 187 (160–206) 0.007
LDL(mg/dl) 137 (105–159) 125 (103–141) 0.020
HOMA: Homeostatic Model Assessment, BMI: body mass index,  CRP: C-reactive protein, AST: alanine amino transferase,  ASP: aspartate amino 
transferase, GGT: gamma glutamyl transferase, TSH: thyroid stimulating hormone 
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leukocytes and GGT (<0.001, <0.001, p = 0.002, p = 0.005 
and p = 0.002 respectively). In this subgroup, higher levels 
of total and LDL cholesterol were observed (p = 0.007 and 
p = 0.020, respectively). Liver transaminases (ALT and 
AST) were significantly higher in insulin-resistant patients 
on admission, during ICCU stay and at discharge. 
In our series, C-RP positivity was present in 157 patients 
(157/286, 54.9%). As shown in Figure 1, patients with C-RP 
positivity showed significantly higher values of admission 
and peak glucose (p = 0.027 and p = 0.001 respectively) in 
the lack of differences in HOMA positivity. 
Linear regression analysis (Figure 2) showed that in our 
series admission glycaemia was directly and significantly 
correlated with insulin values (p < 0.001). 
Non-parametric correlation (Spearman’s rho) showed 
that HOMA index was significantly correlated with BMI 
(r = 0.242; p < 0.0001) and HbA
1c
 (r = 0.189; p < 0.001).
At multivariable backward linear regression analysis 
(Table 4), glycaemia was directly related to leukocyte count 
(p = 0.0003), age (p = 0.0001), creatine kinase isoform MB 
(CK-MB) (p = 0.00278) and lactate (p < 0.0001). Insulin 
was directly and significantly related to glycaemia (p = 
0.0006), BMI (p = 0.00028) and lactate (p = 0.0096).
At multivariable linear regression analysis the following 
variables were independently associated with in-ICCU 
mortality: eGFR (1 ml/min per 1.73m2 step) (OR 0.96; 95% 
confidence interval [CI] 0.91–1.00; p = 0.052), PCI failure 
(OR 9.00; 95% CI 1.06–76.4; p = 0.044), TnI (1 ng/ml 
step) (OR 1.003; 95% CI 1.000–1.006; p = 0.031) and 
admission glycaemia (1 mg/ml step) (OR 1.02; 95% CI 
1.006–1.029; p = 0.002). Hosmer–Lemeshow goodness-of-
fit χ2: 2.850; p = 0.943. Hagelkerke R square: 0.538.
Discussion 
The main finding of the present investigation is that, in 
acute phase of STEMI patients without previously known 
diabetes submitted to mechanical revascularisation, insulin 
secretion is strictly related to BMI, apart from glucose lev-
els. Also, increased glucose values can be mainly related to 
the acute inflammatory response (as indicated to leukocyte 
count and C-RP), to age and to the degree of myocardial 
damage (as inferred by CK-MB). 
Data on insulin secretion in acute myocardial infarction 
are scarce, conflicting and mainly concerning the pre-
thrombolytic and thrombolytic era. While some studies 
documented a failure of insulin response following acute 
myocardial infarction,3,24,25 others reported that plasma 
insulin is high in this setting.25,26 Interestingly, insulin val-
ues were related to infarct size in MI patients not submitted 
Admission glycemia (mg/dl)
Peak glucose (mg/dl)
HOMA positivity (%)
0
20
40
60
80
100
120
140
160
CRP positivity
CRP negativity
p = 0.027
p = 0.001
p = ns
Figure 1. Comparison between patients with and without C-RP positivity. 
CRP: C-reactive protein, HOMA: Homeostatic Model Assessment
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to reperfusion,27 whereas this relation was not detectable in 
patients submitted to thrombolysis.26 In the era of mechani-
cal reperfusion, Nishio et al.13 identified, by means of 
HOMA index, two different subgroups among 61 non-dia-
betic MI patients: the non-insulin resistant group and the 
insulin resistant (IR) group, which consisted of transient 
IR, which correlated with stress hormones, and continuous 
IR, which correlated with leptin (associated with endothe-
lial dysfunction) thus contributing to restenosis after coro-
nary stenting at four-month follow-up. In our investigation 
(including 286 non-diabetic STEMI patients), BMI is 
related to insulin secretion and to the development of 
acute insulin resistance, as indicated by HOMA positivity. 
Moreover, insulin resistant patients showed an impairment 
of liver function as indicated by higher transaminases (both 
on admission and at discharge) and higher values of total 
cholesterol. According to our data, non-diabetic STEMI 
patients who develop acute insulin resistance in the early 
phase share some common features with chronic insulin 
resistance,28 such as the relation with BMI and the associa-
tion with liver impairment (as inferred by increased 
transaminases) and increased cholesterol values. However, 
the underlying mechanisms of acute insulin resistance in 
the early phase of STEMI after revascularisation are far 
from fully understood and the management of these patients 
has not been defined. 
On the other hand, according to our results, there are 
three main factors affecting glucose levels in the acute 
phase of non-diabetic STEMI submitted to PCI: the degree 
of the inflammatory response, the extent of myocardial 
damage, and age, which, together, can contribute a strong 
prognostic role of hyperglycaemia for early mortality in 
STEMI patients.4 The relation between hyperglycaemia 
and inflammation has been previously described in healthy 
subjects29,30 and in critically ill patients.31 In patients with 
acute myocardial infarction, hyperglycaemia, measured on 
hospital admission, was associated with increased inflam-
matory markers (C-RP and IL-18), enhanced cytotoxic 
T-cell activity and reduced expression of T cells implicated 
in the limitation of the immune process, thus increasing 
immune stimulation.32 We recently observed that glucose 
values, measured after mechanical revascularisation, were 
associated with the inflammatory response.11 
The relationship between hyperglycaemia and infarct size 
is controversial, with some studies showing no or weak cor-
relation.3,33 On the other hand, in previous studies by oth-
ers34-36 and us,11 infarct size, measured by enzymatic methods 
(CPK and CPK-MB) and by troponin I, was larger in STEMI 
patients with hyperglycaemia compared with those without. 
Recently,37 in STEMI patients treated with PCI, hyperglycae-
mia on admission was associated with larger infarct size 
determined by SPECT, and hyperglycaemia itself was an 
independent predictor of infarct size when adjusted for con-
founding variables (i.e. sex and age). Multiple physiological 
studies demonstrated that hyperglycaemia may have a direct 
detrimental effect on ischemic myocardium through a vari-
ety of mechanisms (such as decreasing collateral circula-
tion38 and promoting apoptosis39). On the other hand, 
excessive stress-mediated release of counter-regulatory hor-
mones (i.e. catecholamines and glucagon) caused by a 
greater degree of myocardial damage can account, at least in 
part, for the extent of hyperglycaemia40 
Few data are so far available on the ‘age effect’ on glu-
cose metabolism in the early phase of acute myocardial 
Table 4. Multivariable linear regression analysis.
Outcome: glycaemia
Absolute 
coefficient
CI (95%) Standard 
coefficient
p-value
Lactate 0.101 0.066–0.0136 0.356 <0.0001
Leukocyte 
count
0.029 0.014–0.045 0.233 0.0003
Age 0.010 0.005–0.015 0.232 0.0001
CK-MB 0.0003 0.0001–0.0005 0.144 0.0278
Constant 0.15 -0.25–0.54  0.46
Outcome: insulin
Glycaemia 6.4560 2.80–10.12 0.263 0.0006
BMI 0.7770 0.271–1.283 0.200 0.0028
Lactate 1.3590 0.334–2.384 0.2 0.0096
Constant -20.6 -37.8 -3.47 0.0187
CK-MB: creatine kinase isoform MB, BMI: body mass index
Figure 2. Correlation between insulin and glucose values in all 
STEMI patients included in the study.
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infarction. Kosiborod et al.5 observed that elevated glucose 
is associated with increased mortality in elderly acute myo-
cardial infarction and our group recently reported23 that 
older STEMI patients showed the highest glucose levels 
and the poorest glycaemic control during ICCU stay in the 
lack of differences in insulin resistance incidence. These 
finding were confirmed after exclusion of patients with 
poor glycaemic control in the previous 2–3 months (that is, 
patients with HbA1c >6.5%). We supposed that the higher 
glucose values after myocardial injury observed in elderly 
STEMI patients could probably be related (beyond the age 
effect on beta cell mass and sensitivity) to the age-related 
differences in pancreatic and/or hepatic sensitivity to 
β-adrenergic signals.41,42 The present investigation further 
confirms these finding by documenting that glucose values 
are significantly related to age. 
In conclusion, in early phase STEMI patients without 
previously known diabetes, the acute glucose dysmetabo-
lism is quite complex, comprising increased glucose values 
and the development of insulin resistance. While insulin 
secretion and acute insulin resistance can be strictly related 
to BMI, the degree of inflammatory activation, myocardial 
damage, and age are able to influence glucose values in the 
early phase of non-diabetic STEMI submitted to mechani-
cal revascularisation. Further studies are needed to estab-
lish whether acute insulin resistant STEMI patients deserve 
a different (more aggressive) treatment. 
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